Your Series A Investors Have Rights That Block the Series B Lead You Want

Series B leads do not just evaluate your metrics. They evaluate whether they can actually step into the governance role they need. If your Series A documents give existing investors the power to block new securities, veto charter amendments, control board composition, or withhold consent on financing terms, a new lead may walk away before you ever get to price negotiation.

This is one of the most common hidden blockers in a Series B process, and it is covered in depth in the broader guide to cap table issues that can kill a Series B before investors even read your deck. The governance layer is where many founders discover that "standard" early investor terms have created structural problems they cannot solve quickly.

The core issue in plain terms: A new lead typically needs 15 to 20 percent ownership, a board seat with real authority, and clean approval mechanics before it will wire funds. If your existing investor documents create veto points over any of those conditions, the lead cannot get the governance package it requires, and the deal stalls.

Key takeaways:

• Protective provisions in your charter can require existing preferred holder consent before you can issue new preferred stock at all.
• Series-specific voting means a single small investor bloc can block a financing decision even if everyone else approves.
• Preferred-director reserved matters can give a legacy investor a board-level veto over covenants your new lead insists on.
• When governance blockers delay or weaken a Series B, founders pay through worse economics, bigger dilution, or a failed process.

The Four Rights That Create the Blockage

According to the NVCA model financing documents, updated through 2026, four categories of investor rights appear in nearly every US venture financing. Each one is legitimate on its own. The problem is how they interact with a new lead's requirements.

As Elego's 2026 governance analysis notes, governance terms often shape a founder's day-to-day experience of running a company more directly than economic provisions do. At Series B, they shape whether the round closes at all.

Where the Series B Lead Gets Stuck

A new lead arrives with a standard set of closing conditions. Each one can collide with existing investor rights in a different way.

1. The lead needs to issue a new series of preferred stock. Issuing Series B preferred almost always requires amending the charter. Most Series A protective provisions require existing preferred holder consent before the company can create a new class of stock that ranks senior to or on the same level as the existing series. If even one Series A investor withholds consent, the round cannot close on the terms the lead requires.

2. The lead wants a board seat and a rebalanced board. A typical Series B board structure moves toward two common directors, two investor directors, and one independent. If the current board was set at Series A and changing its size requires preferred holder approval, the company needs a separate consent process before it can offer the lead the seat it expects. That process takes time, and uncooperative investors can use it as leverage.

3. The lead requires operating covenants that need board approval. Series B term sheets often include budget approval rights, hiring thresholds, and spending limits. If the existing preferred director has a reserved-matters list that requires their affirmative vote on those same actions, the lead's director cannot function independently. One legacy director can block board-level decisions without ever calling a stockholder vote.

4. Series-specific voting lets a small holder block the whole round. This is the most underestimated risk. When protective provisions require approval from holders of each series separately, rather than all preferred voting as one class, a small Series A investor holding a minority of the total preferred can veto a transaction that every other investor supports. Glencoyne's analysis illustrates this clearly: with 1,000,000 Series A shares and 500,000 Series B shares outstanding, a holder of just 251,000 Series A shares can block a deal under each-series voting, even if every other investor approves.

Why This Turns Into Hidden Dilution, Not Just Governance Drama

Most founders treat governance friction as a legal problem to hand off to counsel. It is actually a pricing problem.

When a new lead cannot get the governance package it needs, it does not usually walk away immediately. It reprices the deal to compensate for the risk and friction it is absorbing. That repricing shows up in ways that are easy to miss.

What happens when governance is clean:

• The lead sets price and terms based on your metrics and growth trajectory.
• Board composition and approval mechanics are agreed quickly.
• The round closes on the timeline both parties planned.
• Founder dilution reflects the agreed ownership split.

What happens when legacy rights create friction:

• The lead lowers its valuation offer to account for execution risk and consent delays.
• It demands a larger allocation to justify the extra legal and timeline exposure.
• It pushes for harsher protective terms of its own to offset the governance uncertainty it is stepping into.
• It may require an expanded option pool before closing, which dilutes founders on a pre-money basis before the new money arrives.

This is how governance blockers become hidden dilution. The cap table damage is not just from the round itself. It comes from the concessions made to get old investors to cooperate. Founders who have already navigated the hidden dilution risks in a Series A raise often discover a second layer of the same problem at Series B, and it is harder to fix under time pressure.

The real cost: Protective provisions appeared in more than 90 percent of 2025 venture deals according to Cooley market data. These rights are not going away. But their structure, thresholds, and voting mechanics are negotiable, and getting them wrong at Series A compounds into a larger ownership loss at Series B.

The Clauses to Review Before You Launch the Raise

Start with your existing documents, not your pitch deck. Pull the charter, voting agreement, and investors' rights agreement and work through each one before you approach a new lead.

Charter

• Does issuing a new class of preferred require consent from existing preferred holders, and does that consent threshold apply per series or across all preferred as one class?
• Are there board-size change restrictions that require preferred holder approval?
• What debt threshold triggers a consent requirement? Is there an ordinary-course carve-out?
• Do M&A or asset sale approvals require a supermajority of preferred, and does each series vote separately?

Voting Agreement

• Who elects each director seat, and what happens to those seats when a new preferred series is added?
• Is there a provision requiring all preferred to vote as a single class on certain actions, or does each series retain separate voting rights?
• What ownership threshold qualifies an investor as a "major investor" with full information and consent rights? Are any Series A investors near or below that threshold?

Investors' Rights Agreement

• Which actions require the affirmative vote of a preferred director specifically, beyond what the full board approves?
• Are there observer rights that give non-director investors access to board materials, and do those rights include any consent or blocking mechanics?
• Do information rights automatically carry over to a new preferred series, or will they need to be renegotiated?

Understanding how investor consent rights can turn a cap table into a governance hostage situation before Series B is the first step. Identifying the exact clauses in your own documents is the second.

How to Fix It Before a Series B Lead Walks Away

Governance cleanup does not have to happen all at once. It does have to happen before you are in active diligence with a lead that has leverage over you.

Step 1: Push for class-wide preferred voting

Wherever your documents currently require separate series consent, work with counsel to consolidate to a single class-wide preferred vote. Reserve series-specific approval rights only for provisions that are genuinely unique to that series, such as amendments to that series' liquidation preference or anti-dilution mechanics. Everything else should require a majority of all preferred voting together.

Step 2: Add materiality thresholds and ordinary-course carve-outs

Consent triggers with no floor create unnecessary friction. A protective provision that requires preferred approval for any debt, any new hire, or any contract is a problem. Negotiate thresholds that match your actual operating scale: debt above a defined dollar amount, related-party transactions above a separate threshold, and carve-outs for customer contracts, vendor agreements, and ordinary employee equity grants.

Step 3: Rebalance the board and get written waivers before you go to market

Agree on a board structure that a Series B lead can accept before you send the first outreach. If the current board composition requires amendment, obtain the written consents or waivers needed to make that change. A lead that arrives to find a clean five-person board with one open seat moves faster than one that arrives to find a governance dispute it did not expect.

Review your charter, voting agreement, investors' rights agreement, and board approval thresholds before launching a Series B process. The capital stack structure you negotiate at Series B is only as clean as the governance foundation you bring into it.

Frequently Asked Questions‍

Can a single Series A investor block an entire Series B round?

Yes, if your charter includes series-specific protective provisions. When each series of preferred votes separately rather than as one unified class, a holder of a majority of just the Series A shares can veto a covered action, including issuance of new preferred, regardless of how every other investor votes. This is why the class-wide vs. series-specific distinction is one of the first things to check in your charter.

Do board observer rights give investors any real blocking power?

Not directly. Observers cannot vote. But observer rights often come bundled with information rights and sometimes with side-letter commitments that give the observer informal leverage during consent processes. If a major investor holds observer rights and separate series consent rights, the combination can create practical friction even without a formal board vote.

Can a Series B lead force existing investors to waive their protective provisions?

A lead can demand that waivers or amendments be obtained as a closing condition, but it cannot unilaterally override existing investor rights. The company must go back to each rights holder and obtain the required consent. If an investor refuses, the lead's closing condition goes unmet. This is why cleanup before the process starts is far less costly than trying to negotiate waivers under deal pressure.

What is the difference between a protective provision and a board reserved matter?

Protective provisions operate at the stockholder level. They require a vote of preferred holders as a class or by series before the company can take a specified action. Reserved matters operate at the board level. They require the affirmative vote of a specific director, typically the preferred director appointed by the lead investor, before the full board can approve certain decisions. Both can block a Series B lead, but through different mechanisms.

When should founders start reviewing governance documents before a Series B?

At least six months before you plan to begin outreach. Obtaining written waivers, amending charter provisions, and rebalancing the board all require time, legal work, and investor cooperation. Starting this process after a lead has issued a term sheet puts the company in the weakest possible negotiating position.

Does the Series B lead automatically get its own protective provisions?

Yes. A new lead will negotiate its own protective provisions as part of the Series B term sheet. The question is whether those provisions will conflict with, layer on top of, or supersede existing Series A rights. If both series retain independent veto rights over the same categories of actions, every future decision requiring approval becomes a multi-party consent process.

What happens to Series A governance rights if the company does a down round at Series B?

They remain in place unless specifically amended. A down round does not automatically eliminate or reduce prior investor consent rights. In fact, it often makes them harder to renegotiate because existing investors have more leverage when the company needs capital urgently. This is one reason governance cleanup should happen before financial pressure forces the issue.

Continue reading this series:

• How SAFE Notes and Convertible Notes Stack Up and Silently Destroy Your Series B Cap Table
• Super Pro-Rata Rights: How One Aggressive Seed Investor's Outsized Follow-On Allocation Is Crowding Out Your Series B Lead
• Why Your Board Composition Is a Cap Table Problem and How It Kills Series B Before Diligence Starts‍

This isn't for pre-revenue companies or first-time founders. It's for operators at $1M+ ARR, raising $5M to $250M of institutional capital, who've done this before and want the next round architected right. If that's you, schedule a call to discuss HERE.